Work

173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2

Year: 2022

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.03.192

Authors: J. Lu, C.M. Blakely, M. Barve, C.H. Chung, S.N. Waqar, X. Hu, J-P. Delord, M.J. Krzakowski, K. Yonemori, D.T. Chen, D. Klingbiel, S. Heinzmann, C. Le Tourneau

Institutions: University of Southern California, USC Norris Comprehensive Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Mary Crowley Cancer Research Center, Moffitt Cancer Center, Washington University in St. Louis, Fudan University, Fudan University Shanghai Cancer Center, Institut universitaire du cancer de Toulouse Oncopole, The Maria Sklodowska-Curie National Research Institute of Oncology, National Cancer Center Hospital, Genentech, F. Hoffmann-La Roche AG, Université Paris-Saclay, Institut Curie

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4229083890

FWCI: 0.105

Cites:

Cited by: 1

Related to: 10